Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (0JDK)

Market Closed
18 Jun, 15:30
$
2. 05
+0.01
+0.54%
$
- Market Cap
- P/E Ratio
0% Div Yield
29,370 Volume
-1.87 Eps
$ 2.04
Previous Close
Day Range
1.97 2.09
Year Range
1.57 12.48

Summary

0JDK closed Wednesday higher at $2.05, an increase of 0.54% from Tuesday's close, completing a monthly decrease of -43.06% or $1.55. Over the past 12 months, 0JDK stock lost -72.74%.
0JDK is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2025, missed the consensus estimates by -0.36%. On average, the company has fell short of earnings expectations by -0.3%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).
Want to track 0JDK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

0JDK Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , June 20, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) have opportunity to lead the securities fraud class action lawsuit.

Prnewswire | 4 hours ago
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.

Globenewswire | 7 hours ago
Faruqi & Faruqi Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA

Faruqi & Faruqi Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Iovance  between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK , June 20, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Prnewswire | 8 hours ago

Iovance Biotherapeutics, Inc. Dividends

0JDK is not paying dividends to its shareholders.

Iovance Biotherapeutics, Inc. Earnings

7 May 2025 Date
-
Cons. EPS
-
EPS
26 Feb 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS
8 Aug 2024 Date
-
Cons. EPS
-
EPS
0JDK is not paying dividends to its shareholders.
7 May 2025 Date
-
Cons. EPS
-
EPS
26 Feb 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS
8 Aug 2024 Date
-
Cons. EPS
-
EPS

Iovance Biotherapeutics, Inc. (0JDK) FAQ

What is the stock price today?

The current price is $2.05.

On which exchange is it traded?

Iovance Biotherapeutics, Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is 0JDK.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Iovance Biotherapeutics, Inc. ever had a stock split?

Iovance Biotherapeutics, Inc. had 0 splits and the recent split was on Sep 26, 2013.

Iovance Biotherapeutics, Inc. Profile

Biotechnology Industry
Healthcare Sector
Dr. Frederick G. Vogt Esq., J.D., Ph.D. CEO
LSE Exchange
US4622601007 ISIN
US Country
838 Employees
- Last Dividend
26 Sep 2013 Last Split
15 Oct 2010 IPO Date

Overview

Iovance Biotherapeutics, Inc. stands as a commercial-stage biotechnology entity dedicated to developing and commercializing innovative cell therapies. Utilizing autologous tumor infiltrating lymphocyte technology, the company aims to provide treatments for metastatic melanoma alongside other solid tumor cancers within the United States. Originating in 2007 and originally known as Lion Biotechnologies, Inc., the company transitioned to its current name in June 2017. With its headquarters in San Carlos, California, Iovance Biotherapeutics has established numerous strategic collaborations and licensing agreements with prominent institutions and companies across the healthcare and biotechnology sectors. These partnerships extend to WuXi Advanced Therapies, Inc.; National Institutes of Health; National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH, aiming to enhance its offering and impact in cancer treatment.

Products and Services

  • Amtagvi

    Described as a pioneering tumor-derived autologous T cell immunotherapy, Amtagvi is specifically designed for adult patients struggling with unresectable or metastatic melanoma. This product marks Iovance's commitment to offering advanced therapeutic options that leverage the body's immune system to fight cancer.

  • Proleukin

    An interleukin-2 product, Proleukin serves as a treatment solution for patients with metastatic renal cell carcinoma. Through boosting the patient's immune response, it aims at attacking and eliminating cancer cells, underscoring the company's expertise in immunotherapy.

  • Lifileucel in combination with pembrolizumab

    This development focuses on treating frontline advanced melanoma patients by combining lifileucel with pembrolizumab. The strategic integration of these treatments exemplifies Iovance's innovative approach towards providing comprehensive care for melanoma patients.

  • LN-145

    Targeted at addressing the challenges in non-small cell lung cancer (NSCLC) and other solid tumor cancers, LN-145 is an ongoing project that aims to expand the therapeutic reach of the company’s immunotherapy solutions.

  • IOV-4001

    Currently in Phase 1/2 IOV-GM1-201 clinical trial, IOV-4001 represents Iovance's commitment to innovating treatment options for NSCLC. This exploration into new therapies highlights the company’s dedication to contributing significant advancements in cancer treatment.

  • Lifileucel for Gynecological Cancers

    Another pivotal area of development, the application of lifileucel for treating gynecological cancers, signifies Iovance's broader endeavor to tackle a variety of cancer types with its cell therapy technologies.

Contact Information

Address: 825 Industrial Road
Phone: 650 260 7120